Cargando…
Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543776/ https://www.ncbi.nlm.nih.gov/pubmed/33039499 http://dx.doi.org/10.1016/j.jinf.2020.10.005 |
| _version_ | 1783591732052492288 |
|---|---|
| author | Bi, Jianping Wang, Sheng Wang, Yajie Yang, Dongqin Verma, Vivek Huang, Jing Han, Guang |
| author_facet | Bi, Jianping Wang, Sheng Wang, Yajie Yang, Dongqin Verma, Vivek Huang, Jing Han, Guang |
| author_sort | Bi, Jianping |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7543776 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75437762020-10-09 Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection Bi, Jianping Wang, Sheng Wang, Yajie Yang, Dongqin Verma, Vivek Huang, Jing Han, Guang J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2021-03 2020-10-08 /pmc/articles/PMC7543776/ /pubmed/33039499 http://dx.doi.org/10.1016/j.jinf.2020.10.005 Text en © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Bi, Jianping Wang, Sheng Wang, Yajie Yang, Dongqin Verma, Vivek Huang, Jing Han, Guang Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection |
| title | Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection |
| title_full | Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection |
| title_fullStr | Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection |
| title_full_unstemmed | Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection |
| title_short | Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection |
| title_sort | effect of administering subsequent immune checkpoint inhibition in cancer patients with prior covid-19 infection |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543776/ https://www.ncbi.nlm.nih.gov/pubmed/33039499 http://dx.doi.org/10.1016/j.jinf.2020.10.005 |
| work_keys_str_mv | AT bijianping effectofadministeringsubsequentimmunecheckpointinhibitionincancerpatientswithpriorcovid19infection AT wangsheng effectofadministeringsubsequentimmunecheckpointinhibitionincancerpatientswithpriorcovid19infection AT wangyajie effectofadministeringsubsequentimmunecheckpointinhibitionincancerpatientswithpriorcovid19infection AT yangdongqin effectofadministeringsubsequentimmunecheckpointinhibitionincancerpatientswithpriorcovid19infection AT vermavivek effectofadministeringsubsequentimmunecheckpointinhibitionincancerpatientswithpriorcovid19infection AT huangjing effectofadministeringsubsequentimmunecheckpointinhibitionincancerpatientswithpriorcovid19infection AT hanguang effectofadministeringsubsequentimmunecheckpointinhibitionincancerpatientswithpriorcovid19infection |